Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Alan Meds vs Ilant Health

Alan Meds
Graded #99

Higher grade

vs+14.299999999999997
Ilant Health
Graded #408

Lower grade

The verdict

Alan Meds takes it — 71.1/100 to 56.8/100.

Alan Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth platform offering compounded semaglutide and tirzepatide with multiple administration formats including microdosing and oral options.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAlan Meds +27
72
45
Dose & formulationAlan Meds +35
75
40
Clinical oversightIlant Health +1
82
83
Labs & monitoringIlant Health +8
53
61
FulfillmentAlan Meds +16
78
62
Contract termsEven
55
55
Alan Meds · left barIlant Health · right bar

The numbers

MetricAlan MedsIlant Health
WeighScore71.1/10056.8/100
GradeCC
Scorecard rank#99#408
Semaglutide$158/mo (compounded)Not disclosed
Tirzepatide$295/mo (compounded)Not disclosed
Coverage46 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Alan Meds

Graded #99 · C

Strengths

  • Aggressively low monthly pricing
  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access
  • Multiple administration formats

Where it loses points

  • Limited public information on program details
Ilant Health

Graded #408 · C

Strengths

  • Value-based, outcomes-driven obesity care model
  • Includes GLP-1 medications with transparent drug pricing for sponsors
  • Care team of board-certified obesity providers and behavioral specialists
  • Dietitians and peer navigators support adherence
  • Data-driven stratification targets the right interventions

Where it loses points

  • Distributed via employers and health plans, not direct cash-pay
  • Individuals generally cannot enroll without sponsor coverage
  • No public consumer pricing for GLP-1
  • Access gated behind organizational buyers
  • Not suited to consumers wanting direct-to-door GLP-1

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard